Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Nanomedicines: promises and reality.

Lagarce F.

Drug Discov Today. 2020 Jan 21. pii: S1359-6446(20)30027-1. doi: 10.1016/j.drudis.2020.01.001. [Epub ahead of print] No abstract available.

PMID:
31978388
2.

Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity.

Briot T, Roger E, Bou Haidar N, Bejaud J, Lautram N, Guillet C, Thépot S, Legeay S, Lagarce F.

Int J Nanomedicine. 2019 Mar 26;14:2091-2102. doi: 10.2147/IJN.S190482. eCollection 2019.

3.

Evaluation of lauroyl-gemcitabine-loaded hydrogel efficacy in glioblastoma rat models.

Bastiancich C, Lemaire L, Bianco J, Franconi F, Danhier F, Préat V, Bastiat G, Lagarce F.

Nanomedicine (Lond). 2018 Aug;13(16):1999-2013. doi: 10.2217/nnm-2018-0057. Epub 2018 Sep 11.

PMID:
30204064
4.

Advances in treatment formulations for acute myeloid leukemia.

Briot T, Roger E, Thépot S, Lagarce F.

Drug Discov Today. 2018 Dec;23(12):1936-1949. doi: 10.1016/j.drudis.2018.05.040. Epub 2018 Jun 2. Review.

5.

Successful treatment of a recurrent Aspergillus niger otomycosis with local application of voriconazole.

Chappe M, Vrignaud S, de Gentile L, Legrand G, Lagarce F, Le Govic Y.

J Mycol Med. 2018 Jun;28(2):396-398. doi: 10.1016/j.mycmed.2018.03.009. Epub 2018 Apr 16.

PMID:
29673769
6.

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia.

Briot T, Roger E, Lautram N, Verger A, Clavreul A, Lagarce F.

Int J Nanomedicine. 2017 Nov 23;12:8427-8442. doi: 10.2147/IJN.S147659. eCollection 2017.

7.

Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats.

Hureaux J, Lacoeuille F, Lagarce F, Rousselet MC, Contini A, Saulnier P, Benoit JP, Urban T.

Int J Nanomedicine. 2017 Nov 8;12:8159-8170. doi: 10.2147/IJN.S146740. eCollection 2017.

8.

Gemcitabine and glioblastoma: challenges and current perspectives.

Bastiancich C, Bastiat G, Lagarce F.

Drug Discov Today. 2018 Feb;23(2):416-423. doi: 10.1016/j.drudis.2017.10.010. Epub 2017 Oct 23. Review.

PMID:
29074439
9.

Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection.

Bastiancich C, Bianco J, Vanvarenberg K, Ucakar B, Joudiou N, Gallez B, Bastiat G, Lagarce F, Préat V, Danhier F.

J Control Release. 2017 Oct 28;264:45-54. doi: 10.1016/j.jconrel.2017.08.019. Epub 2017 Aug 19.

PMID:
28830791
10.

Cytotoxicity and genotoxicity of lipid nanocapsules.

Le Roux G, Moche H, Nieto A, Benoit JP, Nesslany F, Lagarce F.

Toxicol In Vitro. 2017 Jun;41:189-199. doi: 10.1016/j.tiv.2017.03.007. Epub 2017 Mar 18.

PMID:
28323104
11.

Models for drug absorption from the small intestine: where are we and where are we going?

Billat PA, Roger E, Faure S, Lagarce F.

Drug Discov Today. 2017 May;22(5):761-775. doi: 10.1016/j.drudis.2017.01.007. Epub 2017 Jan 20. Review.

PMID:
28115264
12.

Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas.

Bouguéon G, Lagarce F, Martin L, Pailhoriès H, Bastiat G, Vrignaud S.

Int J Pharm. 2016 Jul 25;509(1-2):279-284. doi: 10.1016/j.ijpharm.2016.05.064. Epub 2016 Jun 1.

PMID:
27260135
13.

How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?

Malhaire H, Gimel JC, Roger E, Benoît JP, Lagarce F.

Adv Drug Deliv Rev. 2016 Nov 15;106(Pt B):320-336. doi: 10.1016/j.addr.2016.03.011. Epub 2016 Apr 4. Review.

PMID:
27058155
14.

Nucleic-Acid Delivery Using Lipid Nanocapsules.

Lagarce F, Passirani C.

Curr Pharm Biotechnol. 2016;17(8):723-7. Review.

PMID:
27033510
15.

Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma.

Bastiancich C, Vanvarenberg K, Ucakar B, Pitorre M, Bastiat G, Lagarce F, Préat V, Danhier F.

J Control Release. 2016 Mar 10;225:283-93. doi: 10.1016/j.jconrel.2016.01.054. Epub 2016 Jan 30.

PMID:
26829100
16.

Stability of micafungin sodium solutions at different concentrations in glass bottles and syringes.

Briot T, Vrignaud S, Lagarce F.

Int J Pharm. 2015 Aug 15;492(1-2):137-40. doi: 10.1016/j.ijpharm.2015.07.019. Epub 2015 Jul 14.

PMID:
26187166
17.

Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide.

Messaoudi K, Clavreul A, Lagarce F.

Drug Discov Today. 2015 Jun;20(6):772-9. doi: 10.1016/j.drudis.2015.02.014. Epub 2015 Apr 16. Review.

PMID:
25892456
18.

Design and stability study of a paediatric oral solution of methotrexate 2 mg/ml.

Vrignaud S, Briot T, Launay A, Kempf M, Lagarce F.

Int J Pharm. 2015 Jun 20;487(1-2):270-3. doi: 10.1016/j.ijpharm.2015.04.016. Epub 2015 Apr 13.

PMID:
25882013
19.

Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.

Messaoudi K, Clavreul A, Lagarce F.

Drug Discov Today. 2015 Jul;20(7):899-905. doi: 10.1016/j.drudis.2015.02.011. Epub 2015 Mar 2. Review.

PMID:
25744176
20.

In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor.

Groo AC, Bossiere M, Trichard L, Legras P, Benoit JP, Lagarce F.

Nanomedicine (Lond). 2015 Mar;10(4):589-601. doi: 10.2217/nnm.14.124.

PMID:
25723092
21.

Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.

Danhier F, Messaoudi K, Lemaire L, Benoit JP, Lagarce F.

Int J Pharm. 2015 Mar 15;481(1-2):154-61. doi: 10.1016/j.ijpharm.2015.01.051. Epub 2015 Jan 30.

PMID:
25644286
22.

Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide.

Messaoudi K, Saulnier P, Boesen K, Benoit JP, Lagarce F.

Int J Nanomedicine. 2014 Mar 24;9:1479-90. doi: 10.2147/IJN.S59134. eCollection 2014.

23.

Mucus models to evaluate nanomedicines for diffusion.

Groo AC, Lagarce F.

Drug Discov Today. 2014 Aug;19(8):1097-108. doi: 10.1016/j.drudis.2014.01.011. Epub 2014 Jan 31. Review.

PMID:
24491319
24.

Development of 2D and 3D mucus models and their interactions with mucus-penetrating paclitaxel-loaded lipid nanocapsules.

Groo AC, Mircheva K, Bejaud J, Ailhas C, Panaiotov I, Saulnier P, Ivanova T, Lagarce F.

Pharm Res. 2014 Jul;31(7):1753-65. doi: 10.1007/s11095-013-1280-4. Epub 2014 Jan 28.

PMID:
24469905
25.

Comparison of Raman spectroscopy vs. high performance liquid chromatography for quality control of complex therapeutic objects: model of elastomeric portable pumps filled with a fluorouracil solution.

Bourget P, Amin A, Vidal F, Merlette C, Lagarce F.

J Pharm Biomed Anal. 2014 Mar;91:176-84. doi: 10.1016/j.jpba.2013.12.030. Epub 2014 Jan 3.

PMID:
24463044
26.

Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery.

Groo AC, Saulnier P, Gimel JC, Gravier J, Ailhas C, Benoit JP, Lagarce F.

Int J Nanomedicine. 2013;8:4291-302. doi: 10.2147/IJN.S51837. Epub 2013 Nov 7.

27.

Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide.

Saliou B, Thomas O, Lautram N, Clavreul A, Hureaux J, Urban T, Benoit JP, Lagarce F.

Eur J Pharm Sci. 2013 Oct 9;50(2):172-80. doi: 10.1016/j.ejps.2013.06.013. Epub 2013 Jul 4.

PMID:
23831519
28.

Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study.

Ramadan A, Lagarce F, Tessier-Marteau A, Thomas O, Legras P, Macchi L, Saulnier P, Benoit JP.

Int J Nanomedicine. 2011;6:2941-51. doi: 10.2147/IJN.S25791. Epub 2011 Nov 21.

29.

Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration.

Roger E, Lagarce F, Benoit JP.

Eur J Pharm Biopharm. 2011 Sep;79(1):181-8. doi: 10.1016/j.ejpb.2011.01.021. Epub 2011 Feb 12.

PMID:
21303693
30.

Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells.

Roger E, Lagarce F, Garcion E, Benoit JP.

Eur J Pharm Sci. 2010 Aug 11;40(5):422-9. doi: 10.1016/j.ejps.2010.04.015. Epub 2010 May 11.

PMID:
20438839
31.

Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery.

Roger E, Lagarce F, Garcion E, Benoit JP.

Nanomedicine (Lond). 2010 Feb;5(2):287-306. doi: 10.2217/nnm.09.110. Review.

PMID:
20148639
32.

Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice.

Hureaux J, Lagarce F, Gagnadoux F, Rousselet MC, Moal V, Urban T, Benoit JP.

Pharm Res. 2010 Mar;27(3):421-30. doi: 10.1007/s11095-009-0024-y.

PMID:
20054705
33.

Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis.

Roger E, Lagarce F, Garcion E, Benoit JP.

J Control Release. 2009 Dec 3;140(2):174-81. doi: 10.1016/j.jconrel.2009.08.010. Epub 2009 Aug 20.

PMID:
19699246
34.

Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel.

Hureaux J, Lagarce F, Gagnadoux F, Vecellio L, Clavreul A, Roger E, Kempf M, Racineux JL, Diot P, Benoit JP, Urban T.

Eur J Pharm Biopharm. 2009 Oct;73(2):239-46. doi: 10.1016/j.ejpb.2009.06.013. Epub 2009 Jun 26.

PMID:
19560538
35.

The gastrointestinal stability of lipid nanocapsules.

Roger E, Lagarce F, Benoit JP.

Int J Pharm. 2009 Sep 11;379(2):260-5. doi: 10.1016/j.ijpharm.2009.05.069. Epub 2009 Jun 12.

PMID:
19524655
36.

The adaptation of lipid nanocapsule formulations for blood administration in animals.

Hureaux J, Lagarce F, Gagnadoux F, Clavreul A, Benoit JP, Urban T.

Int J Pharm. 2009 Sep 11;379(2):266-9. doi: 10.1016/j.ijpharm.2009.05.033. Epub 2009 May 23.

PMID:
19467305
37.

Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.

Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP.

Pharm Res. 2006 Jun;23(6):1243-50. Epub 2006 May 25.

PMID:
16715372
38.

Development and characterization of interleukin-18-loaded biodegradable microspheres.

Lagarce F, Garcion E, Faisant N, Thomas O, Kanaujia P, Menei P, Benoit JP.

Int J Pharm. 2006 May 18;314(2):179-88. Epub 2006 Mar 3.

PMID:
16515850
39.

Development of new polymer-based particulate systems for anti-glioma vaccination.

Sapin A, Garcion E, Clavreul A, Lagarce F, Benoit JP, Menei P.

Int J Pharm. 2006 Feb 17;309(1-2):1-5. Epub 2005 Dec 28.

PMID:
16386390
40.

Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation.

Lagarce F, Faisant N, Desfontis JC, Marescaux L, Gautier F, Richard J, Menei P, Benoit JP.

Eur J Pharm Biopharm. 2005 Oct;61(3):171-80. Epub 2005 Jun 20.

PMID:
15967653
41.

Biopharmaceutics of intrathecal baclofen-loaded microparticles in a goat model.

Lagarce F, Faisant N, Desfontis JC, Marescaux L, Gautier F, Holopherne D, Rousselet MC, Menei P, Benoit JP.

Int J Pharm. 2005 Jul 14;298(1):68-79.

PMID:
15919163
42.

Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model.

Lagarce F, Renaud P, Faisant N, Nicolas G, Cailleux A, Richard J, Menei P, Benoit JP.

Eur J Pharm Biopharm. 2005 Apr;59(3):449-59.

PMID:
15760725
43.

Oxaliplatin loaded PLAGA microspheres: design of specific release profiles.

Lagarce F, Cruaud O, Deuschel C, Bayssas M, Griffon-Etienne G, Benoit J.

Int J Pharm. 2002 Aug 21;242(1-2):243-6.

PMID:
12176255
44.

[New data in the field of pesticides].

LAGARCE F.

Prod Pharm. 1958 Feb;13(2):94-8. French. No abstract available.

PMID:
13567831
45.

[A new chlorinated insecticide, aldrin].

LAGARCE F.

Prod Pharm. 1955 Jul;10(7):435-6. French. No abstract available.

PMID:
13254875

Supplemental Content

Loading ...
Support Center